company background image
2US logo

NextCure MUN:2US Stock Report

Last Price

€1.40

Market Cap

€50.8m

7D

0%

1Y

n/a

Updated

27 Mar, 2024

Data

Company Financials +

2US Stock Overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

2US fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NextCure, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NextCure
Historical stock prices
Current Share PriceUS$1.40
52 Week HighUS$1.47
52 Week LowUS$1.40
Beta0.36
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Change-83.59%
5 Year Changen/a
Change since IPO-92.44%

Recent News & Updates

Recent updates

Shareholder Returns

2USDE BiotechsDE Market
7D0%2.1%1.9%
1Yn/a37.0%7.3%

Return vs Industry: Insufficient data to determine how 2US performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 2US performed against the German Market.

Price Volatility

Is 2US's price volatile compared to industry and market?
2US volatility
2US Average Weekly Movementn/a
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2US has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2US's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201582Michael Richmanhttps://www.nextcure.com

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.

NextCure, Inc. Fundamentals Summary

How do NextCure's earnings and revenue compare to its market cap?
2US fundamental statistics
Market cap€50.80m
Earnings (TTM)-€57.97m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2US income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$62.72m
Earnings-US$62.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.25
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 2US perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.